Gastrointestinal tract involvement in systemic sclerosis
https://doi.org/10.14412/1996-7012-2026-2-72-77
Abstract
Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by generalized microangiopathy and fibrosis of the skin and internal organs. The gastrointestinal (GI) tract is the most frequently affected organ system in SSc, and signs of GI involvement often occur at early stages of the disease. Currently, approved treatment options for GI involvement in SSc are limited, while approaches to treatment of different GI segments’ differ fundamentally. Despite its high prevalence, gastroenterological complications of SSc are insufficiently covered in the literature. This review analyzes current methods for the diagnosis and treatment of GI involvement in SSc.
About the Author
R. T. Alekperov
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Russian Federation
Russian Federation
Rizvan Tair ogly Alekperov
61/2, Shchepkina Street, Moscow 129110
References
1. Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009 Jun:48 Suppl 3:iii36-9. doi: 10.1093/rheumatology/ken485.
2. Poudel DR, Jayakumar D, Danve A, et al. Determinants of mortality in systemic sclerosis: a focused review. Rheumatol Int. 2018 Oct; 38(10):1847-1858. doi: 10.1007/s00296-017-3826-y.
3. von Mühlenbrock C, Madrid AM, Defilippi C, et al. Diffuse Gastrointestinal Motor Compromise in Patients with Scleroderma: Utility of Minimally Invasive Techniques. Dig Dis Sci. 2024 Jan;69(1):191-199. doi: 10.1007/s10620-023-08151-5.
4. Volkmann ER, McMahan Z. Gastrointestinal involvement in systemic sclerosis: Pathogenesis, assessment, and treatment. Curr Opin Rheumatol. 2022 Nov 1;34(6):328-336. doi: 10.1097/BOR.0000000000000899.
5. Jimenez SA, Mendoza FA, Piera Velazquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol. 2025 Apr 16:16: 1551911. doi: 10.3389/fimmu.2025.1551911.
6. Kumar S, Singh J, Rattan S, et al. Review article: pathogenesis and clinical manifestations of gastrointestinal involvement in systemic sclerosis. Aliment Pharmacol Ther. 2017 Apr;45(7):883-898. doi: 10.1111/apt.13963.
7. Tian XP, Zhang X. Gastrointestinal complications of systemic sclerosis. World J Gastroenterol. 2013 Nov 7;19(41):7062-8. doi: 10.3748/wjg.v19.i41.7062.
8. Kumar S, Singh J, Kedika R, et al. Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIG. Am J Physiol Gastrointest Liver Physiol. 2016 Jun 1;310(11):G1052-60. doi: 10.1152/ajpgi.00034.2016.
9. Ayla AY, Kalavar NR, Pimentel M, et al. Anti-muscarinic 3 antibodies associate with a severe clinical phenotype in patients with systemic sclerosis. Rheumatology (Oxford). 2025 Oct 1;64(10):5230-5237. doi: 10.1093/ rheumatology/keaf197.
10. Bixio R, Bertelle D, Bertoldo E, et al. The potential pathogenic role of gut microbiota in rheumatic diseases: a human-centred narrative review. Intern Emerg Med. 2024 Jun; 19(4):891-900. doi: 10.1007/s11739-023-03496-1.
11. Thonhofer R, Siegel C, Trummer M, Graninger W. Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatol Int. 2012 Jan;32(1):165-8. doi: 10.1007/s00296-010-1595-y.
12. Salaffi F, Di Carlo M, Carotti M, et al. Relationship between interstitial lung disease and oesophageal dilatation on chest high-resolution computed tomography in patients with systemic sclerosis: a cross-sectional study. Radiol Med. 2018 Sep;123(9):655-663. doi: 10.1007/s11547-018-0894-3.
13. McFarlane IM, Bhamra MS, Kreps A, et al. Gastrointestinal manifestations of systemic sclerosis. Rheumatology (Sunnyvale). 2018;8(1):235. doi: 10.4172/2161-1149.1000235.
14. Snyder DL, Crowell MD, Kahn A, et al. Prevalence of Barrett’s Esophagus in Female Patients With Scleroderma. Am J Gastroenterol. 2021 Mar 1;116(3):517-521. doi: 10.14309/ajg.0000000000001109.
15. Rutka K, Galkowski A, Karaszewska K, Lebkowska U. Imaging in Diagnosis of Systemic Sclerosis. J Clin Med. 2021 Jan 12; 10(2):248. doi: 10.3390/jcm10020248.
16. Khanna D, Nagaraja V, Gladue H, et al. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol. 2013 Nov;25(6):700-6. doi: 10.1097/01.bor.0000434668.32150.e5.
17. Zentilin P, Savarino V, Marabotto E, et al. Esophageal baseline impedance levels allow the identification of esophageal involvement in patients with systemic sclerosis. Semin Arthritis Rheum. 2018 Feb;47(4):569-574. doi: 10.1016/j.semarthrit.2017.08.004.
18. Del Galdo F, Lescoat A, Conaghan PG, et al. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. Ann Rheum Dis. 2025 Jan;84(1):29-40. doi: 10.1136/ard-2024-226430.
19. Shirai Y, Kawami N, Iwakiri K, Kuwana M. Use of vonoprazan, a novel potassiumcompetitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. J Scleroderma Relat Disord. 2022 Feb;7(1): 57-61. doi: 10.1177/23971983211021747.
20. Foocharoen C, Chunlertrith K, Mairiang P, et al. Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial. Rheumatology (Oxford). 2017 Feb;56(2):214-222. doi: 10.1093/rheumatology/kew216.
21. Scheerens C, Tack J, Rommel N. Buspirone, a new drug for the management of patients with ineffective esophageal motility. United European Gastroenterol J. 2015 Jun;3(3): 261-5. doi: 10.1177/2050640615585688.
22. Karamanolis GP, Panopoulos S, Denaxas K, et al. The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial. Arthritis Res Ther. 2016 Sep 1;18(1):195. doi: 10.1186/s13075-016-1094-y.
23. Weston S, Thumshirn M, Wiste J, Camilleri M. Clinical and upper gastrointestinal motility features in systemic sclerosis and related disorders. Am J Gastroenterol. 1998 Jul; 93(7):1085-9. doi: 10.1111/j.1572-0241.1998.00334.x.
24. Marie I, Ducrotte P, Antonietti M, et al. Watermelon stomach in systemic sclerosis: its incidence and management. Aliment Pharmacol Ther. 2008 Aug 15;28(4):412-21. doi: 10.1111/j.1365-2036.2008.03739.x.
25. Sallam H, McNearney TA, Chen JD. Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma). Aliment Pharmacol Ther. 2006 Mar 15;23(6):691-712. doi: 10.1111/j.1365-2036.2006.02804.x.
26. Grover M, Farrugia G, Stanghellini V. Gastroparesis: a turning point in understanding and treatment. Gut. 2019 Dec;68(12): 2238-2250. doi: 10.1136/gutjnl-2019-318712.
27. Camilleri M. Functional Dyspepsia and Gastroparesis. Dig Dis. 2016;34(5):491-9. doi: 10.1159/000445226.
28. Carbone F, Van den Houte K, Clevers E, et al. Prucalopride in gastroparesis: a randomized placebo-controlled crossover study. Am J Gastroenterol. 2019 Aug;114(8):1265-1274. doi: 10.14309/ajg.0000000000000304.
29. Vigone B, Caronni M, Severino A, et al. Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study. Arthritis Res Ther. 2017 Jun 20;19(1): 145. doi: 10.1186/s13075-017-1340-y.
30. Polkowska-Pruszynska B, Gerkowicz A, Szczepanik-Kulak P, Krasowska D. Small intestinal bacterial overgrowth in systemic sclerosis: a review of the literature. Arch Dermatol Res. 2019 Jan;311(1):1-8. doi: 10.1007/s00403-018-1874-0.
31. Sattar B, Chokshi RV. Colonic and anorectal manifestations of systemic sclerosis. Curr Gastroenterol Rep. 2019 Jul 8;21(7):33. doi: 10.1007/s11894-019-0699-0.
32. Marie I, Ducrotte P, Denis P, et al. Outcome of small-bowel motor impairment in systemic sclerosis – a prospective manometric 5-yr follow-up. Rheumatology (Oxford). 2007 Jan;46(1):150-3. doi: 10.1093/rheumatology/kel203.
33. Kaneko M, Sasaki S, Teruya S, et al. Pneumatosis Cystoides Intestinalis in Patients with Systemic Sclerosis: A Case Report and Review of 39 Japanese Cases. Case Rep Gastrointest Med. 2016:2016:2474515. doi: 10.1155/2016/2474515.
34. Brandler JB, Sweetser S, Khoshbin K, et al. Colonic manifestations and complications are relatively under-reported in systemic sclerosis: a systematic review. Am J Gastroenterol. 2019 Dec;114(12):1847-1856. doi: 10.14309/ajg.0000000000000397.
35. Kaniecki T, Abdi T, McMahan ZH. Clinical Assessment of Gastrointestinal Involvement in Patients with Systemic Sclerosis. Med Res Arch. 2020 Oct;8(10):2252. doi: 10.18103/mra.v8i10.2252.
36. Marie I, Ducrotte P, Denis P, et al. Small intestinal bacterial overgrowth in systemic sclerosis. Rheumatology (Oxford). 2009 Oct; 48(10):1314-9. doi: 10.1093/rheumatology/kep226.
37. Tan TC, Chandrasekaran L, Leung YY, et al. Gut microbiome profiling in systemic sclerosis: a metagenomic approach. Clin Exp Rheumatol. 2023 Aug;41(8):1578-1588. doi: 10.55563/clinexprheumatol/jof7nx.
38. Pittman N, Rawn SM, Wang M, et al. Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review. Rheumatology (Oxford). 2018 Oct 1; 57(10):1802-1811. doi: 10.1093/rheumatology/key175.
39. Polkowska-Pruszynska B, Gerkowicz A, Rawicz-Pruszynski K, Krasowska D. Gut microbiome in systemic sclerosis: a potential therapeutic target. Postepy Dermatol Alergol. 2022 Feb;39(1):101-109. doi: 10.5114/ada.2020.101468.
40. Quigley EMM. The spectrum of small intestinal bacterial overgrowth (SIBO). Curr Gastroenterol Rep. 2019 Jan 15;21(1):3. doi: 10.1007/s11894-019-0671-z.
41. Erdogan A, Rao SS, Gulley D, et al. Small intestinal bacte rial overgrowth: duodenal aspiration vs glucose breath test. Neurogastroenterol Motil. 2015 Apr;27(4):481-9. doi: 10.1111/nmo.12516.
42. Ohkubo H, Kessoku T, Tanaka K, et al. Efficacy and safety of rifaximin in patients with chronic intestinal pseudo-obstruction: a randomized, double-blind, placebo-controlled, phase II — a exploratory trial. Biosci Microbiota Food Health. 2024;43(2):135-144. doi: 10.12938/bmfh.2023-080.
43. Ahuja NK, Mische L, Clarke JO, et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis. Semin Arthritis Rheum. 2018 Aug;48(1):111-116. doi: 10.1016/j.semarthrit.2017.12.007.
44. Fretheim H, Chung BK, Didriksen H, et al. Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial. PLoS One. 2020 May 21;15(5):e0232739. doi: 10.1371/journal.pone.0232739.
45. Garcia-Collinot G, Madrigal-Santillan EO, Martinez-Bencomo MA, et al. Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020 Apr; 65(4):1134-1143. doi: 10.1007/s10620-019-05830-0.
46. Fynne L, Worsoe J, Gregersen T, et al. Gastrointestinal transit in patients with systemic sclerosis. Scand J Gastroenterol. 2011 Oct;46(10):1187-93. doi: 10.3109/00365521.2011.603158.
47. D’Angelo G, Stern HS, Myers E. Rectal prolapse in scleroderma: case report and review of the colonic complications of scleroderma. Can J Surg. 1985 Jan;28(1):62-3.
48. Dein E, Kuo PL, Hong YS, et al. Evaluation of risk factors for pseudo-obstruction in systemic sclerosis. Semin Arthritis Rheum. 2019 Dec;49(3):405-410. doi: 10.1016/j.semarthrit.2019.05.005.
49. Valenzuela A, Li S, Becker L, et al. Intestinal pseudo-obstruction in patients with systemic sclerosis: an analysis of the Nationwide Inpatient Sample. Rheumatology (Oxford). 2016 Apr;55(4):654-8. doi: 10.1093/rheumatology/kev393.
50. Boeckxstaens GE, Bartelsman LL, Tytgat GN. Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride. Am J Gastroenterol. 2002 Jan; 97(1):194-7. doi: 10.1111/j.1572-0241.2002. 05396.x.
51. Garros A, Marjoux S, Khouatra C, et al. Prevalence of fecal incontinence in a cohort of systemic sclerosis patients within a regional referral network. United European Gastroenterol J. 2017 Nov;5(7):1046-1050. doi: 10.1177/2050640616688129.
52. Kenefick NJ, Vaizey CJ, Nicholls RJ, et al. Sacral nerve stimulation for faecal incontinence due to systemic sclerosis. Gut. 2002 Dec; 51(6):881-3. doi: 10.1136/gut.51.6.881.
53. Butt SK, Alam A, Cohen R, et al. Lack of effect of sacral nerve stimulation for incontinence in patients with systemic sclerosis. Colorectal Dis. 2015 Oct;17(10):903-7. doi: 10.1111/codi.12969.
54. Al Asari S, Meurette G, Mantoo S, et al. Percutaneous tibial nerve stimulation vs sacral nerve stimulation for faecal incontinence: a comparative case-matched study. Colorectal Dis. 2014 Nov;16(11):O393-9. doi: 10.1111/codi.12680.
Review
For citations:
Alekperov RT. Gastrointestinal tract involvement in systemic sclerosis. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2026;20(3):72-78. (In Russ.) https://doi.org/10.14412/1996-7012-2026-2-72-77
Views:
177
JATS XML
Email this article 
